Trial
NCT04958785
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Triple-Negative Breast Cancer
Intervention
Magrolimab
Why stopped
Sponsor decision to terminate study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-04